A magnetic resonance imaging MRI-based screening program for
individuals at high risk of pancreatic cancer identified pancreatic
lesions in 16 of 40 of patients, of whom 5 five underwent
surgery, according to a report published online by JAMA Surgery.
Marco Del Chiaro, M.D., Ph.D., of the Karolinska Institute,
Stockholm, Sweden, and coauthors analyzed short-term results from an
MRI-based screening program for patients with a genetic risk of
developing pancreatic cancer. The study included 40 patients (24 women and 16 men with an average
age of nearly 50). In 38 of the patients, increased risk of the disease
was based on family history of pancreatic cancer. BRCA2, BRCA1 and p16
gene mutations were identified in some patients. The average study
follow-up was 12. 9 months, with MRI screening repeated after one year
if the initial screen was negative or at six months if there were
unspecific findings or findings that did not indicate surgery. According to the results, MRIs found a pancreatic lesion in 16
patients (40 percent): intraductal papillary mucinous neoplasia, which
can become invasive cancer, in 14 patients (35 percent) and pancreatic
ductal adenocarcinoma in two patients (5 percent). Five patients (12.5
percent) required surgery (3 for pancreatic ductal adenocarcinoma and 2
for intraductal papillary mucinous neoplasia), the remaining 35 continue
under surveillance.
"An MRI-based protocol for the surveillance of individuals at risk
for developing pancreatic cancer seems to detect cancer or premalignant
lesions with good accuracy. The exclusive use of MRI can reduce costs,
increase availability and guarantee the safety of the individuals under
surveillance compared with protocols that are based on more aggressive
methods. However, because of the small number of patients and the
divergent results, this study did not allow evaluation of the efficacy
of MRI as a single screening modality," the study concludes.
This site is for information on the various Chemo treatments and Stem Cell Therapies since 1992. This journey became bitter sweet in 2014, with the passing of my beautiful and dear wife. Sherry, had fought Non - Hodgkins Lymphoma(NHL) since 1990, in and out of remissions time and time again. From T-Cell therapies(1990's) to Dual Cord Blood Transplant(2014), she was in Clinical Trials over the years. This site is for informational purpose only and is not to promote the use of certain therapies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment